Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2023-02-09 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
关于使用部分闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 美康生物科技股份有限公司 regarding the progress of using part of idle raised funds for cash management. It details the approval by the board and supervisory committee, the types of financial products purchased, risk control measures, and the impact on daily operations. The document is relatively short (3153 characters) and focuses on a specific financing activity related to the use of idle raised funds for cash management, including amounts, dates, and expected returns. It is not a full financial report, audit, or earnings release, nor is it a regulatory certification or voting result. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital usage related to idle raised funds management.
2023-02-09 Chinese
关于全资孙公司通过高新技术企业认定的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the recognition of its wholly-owned subsidiaries as high-tech enterprises, including details about certificates, issuing authorities, and the impact on tax benefits. It is a brief disclosure without financial statements or detailed financial analysis. The document length is short (1080 characters), and it serves as an informational announcement rather than a full report. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not about management changes, voting results, or legal proceedings. The content is a regulatory announcement about a corporate event affecting subsidiaries. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-02-09 Chinese
关于控股子公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of a medical device registration certificate by a controlling subsidiary. It includes details about the certificate, product information, and potential impact on company performance. The document is short (1195 characters) and does not contain financial statements or detailed financial analysis. It is an announcement of a regulatory or operational update rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-01-31 Chinese
关于转让孙公司内蒙古盛德医疗器械有限公司股权的公告
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding the transfer of equity in a subsidiary company (Inner Mongolia Shengde Medical Device Co., Ltd.) by Meikang Biotechnology Co., Ltd. It includes transaction background, parties involved, shareholding structure before and after the transfer, financial data of the subsidiary, pricing policy, main terms of the transfer agreement, and the impact on the parent company. The document is a formal announcement of a capital transaction involving a subsidiary's equity transfer, with no indication of it being a full financial report, earnings release, or regulatory certification. It is not a report publication announcement since it contains substantive transaction details and financial data related to the transaction. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as equity transfers.
2023-01-06 Chinese
关于公司官方网站域名和电子邮箱变更的公告
Regulatory Filings Classification · 100% confidence The document is a short announcement (861 characters) from the company 美康生物科技股份有限公司 regarding changes to its official website domain and email address. It contains no financial data, no discussion of financial results, no regulatory certifications, no voting results, no management changes, and no legal or capital structure information. It is simply an operational update to contact information. According to the rules, such brief announcements that do not contain substantive financial or governance information and are not reports themselves fall under Regulatory Filings (RNS).
2023-01-04 Chinese
关于控股子公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of a medical device registration certificate by a controlling subsidiary. It includes details about the certificate, its validity, and potential impact on company performance. The document is short (1000 characters) and serves as a formal disclosure of a regulatory approval event rather than a financial report or detailed management discussion. There is no financial data, no mention of annual or quarterly results, no voting results, no management changes, or other report types. It is a regulatory announcement about a business development event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-01-04 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.